Related Experiment Video
Updated: Jan 29, 2026

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
Liposomal anthracyclines and new treatment approaches for breast cancer
1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University, Baltimore, Maryland 21231-1000, USA. awolf@jhmi.edu
Abstract:
Breast cancer research is entering a new and promising phase, with greater focus on patient quality of life and therapy selection based on specific targets of interest. Growth factor pathway modulators represent an area of increasing interest for clinicians treating various cancer types, including breast cancer. Therapeutic strategies combining cytotoxic drugs with specific targets using small molecules and targeted antibody therapy may help circumvent potential growth factor survival mechanisms in solid tumors. One of the challenges when combining these agents, however, is the potential for pharmacodynamic and pharmacokinetic interactions, making safety an important consideration. An example of a growth factor pathway modulator with clinical application in breast cancer is trastuzumab. Based on its efficacy in metastatic disease, ongoing clinical trials are examining trastuzumab in combination with chemotherapy in the adjuvant setting. Concerns about the cardiac safety of trastuzumab given concomitantly with conventional anthracyclines support ongoing investigations of regimens combining it with liposomal anthracyclines, based on available data indicating a more favorable cardiac safety profile with liposomal formulations.
Insights
New breast cancer therapies focus on patient quality of life and targeted treatments. Combining growth factor pathway modulators like trastuzumab with chemotherapy is under investigation, with a focus on cardiac safety. Liposomal anthracyclines may offer a safer alternative.
Area of Science:
- Oncology
- Pharmacology
Background:
- Breast cancer research is shifting towards improving patient quality of life and personalized therapy.
- Growth factor pathway modulators are increasingly important in cancer treatment, including breast cancer.
Purpose of the Study:
- To explore therapeutic strategies combining cytotoxic drugs with targeted agents for breast cancer.
- To address the safety considerations, particularly pharmacokinetic and pharmacodynamic interactions, when combining therapies.
- To investigate the use of trastuzumab in combination with chemotherapy in the adjuvant setting for breast cancer.
Main Methods:
- Review of clinical trials and available data on growth factor pathway modulators in breast cancer.
- Examination of combination therapy strategies involving cytotoxic drugs, small molecules, and targeted antibody therapy.
- Analysis of safety profiles, with a specific focus on cardiac safety when combining trastuzumab with anthracyclines.
Main Results:
- Trastuzumab is an example of a growth factor pathway modulator with clinical application in breast cancer.
- Ongoing trials are evaluating trastuzumab in combination with chemotherapy in the adjuvant setting.
- Concerns regarding cardiac safety with conventional anthracyclines are driving research into liposomal anthracycline formulations.
Conclusions:
- Combining targeted therapies with chemotherapy holds promise for circumventing cancer survival mechanisms.
- Careful consideration of drug interactions and safety is crucial for combination therapies.
- Liposomal anthracyclines may present a more favorable cardiac safety profile when used with trastuzumab compared to conventional anthracyclines.
Related Concept Videos
Treatment Resistant Cancers
Frustration and Conflict: Approach-Approach, Approach-Avoidance
One common type of conflict is the Approach–Approach Conflict. In this case, a person faces two desirable...
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Information Processing Approach
The Nativist Approach
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...

